Advanced Cell Technology Inc. (ACTC)
-OTC BB 0.08 
0.00(0.63%) Jun 18, 3:58PM EDT
| Prev Close: | 0.08 |
|---|
| Open: | 0.08 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 2.51 |
|---|
| Beta: | 1.26 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.08 - 0.08 |
|---|
| 52wk Range: | 0.05 - 0.10 |
|---|
| Volume: | 3,567,335 |
|---|
| Avg Vol (3m): | 8,693,620 |
|---|
| Market Cap: | 191.42M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.01 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- ACT’s Dr. Robert Lanza to Deliver the Keynote Address at Brigham & Women’s Hospital Regenerative Medicine Center Inaugural SymposiumBusiness Wire(Mon, Jun 10)
- The Fast Paced World Of Advanced Cell Technology: An Interview With Chairman And CEO Gary Rabinat Seeking Alpha(Mon, Jun 3)
- ADVANCED CELL TECHNOLOGY, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements anEDGAR Online(Fri, May 24)
- ACT Appoints Edward Myles as Chief Financial OfficerBusiness Wire(Thu, May 23)
- ADVANCED CELL TECHNOLOGY, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- ACT Confirms Clinical Trial Participant Showed Improvement in Vision from 20/400 to 20/40 Following TreatmentBusiness Wire(Thu, May 16)
- ADVANCED CELL TECHNOLOGY, INC. Files SEC form 8-K, Regulation FD DisclosureEDGAR Online(Thu, May 16)
- A Breakdown Of Advanced Cell Technology's Latest Conference Callat Seeking Alpha(Thu, May 16)
- Scientists create human stem cells through cloningat Reuters(Wed, May 15)
- Advanced Cell Technology's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 9)
- Advanced Cell Technology Announces 2013 First Quarter ResultsBusiness Wire(Thu, May 9)
- ADVANCED CELL TECHNOLOGY, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- Advanced Cell Technology to Host Conference Call to Discuss 2013 First Quarter Results and Provide a Corporate Update on Thursday, May 9thBusiness Wire(Mon, May 6)
- Corporate Profile Advanced Cell Technology Inc.WILink(Sun, May 5)
- Swinging For The Fences With Advanced Cell Technologyat Seeking Alpha(Wed, May 1)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 386.38 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(0-00-31)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Advanced Cell Technology, Inc., a biotechnology company, engages in the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine.
View More